Literature DB >> 17521239

Phenotypic and functional analysis of human fetal liver hematopoietic stem cells in culture.

Pierre Rollini1, Eveline Faes-Van't Hull, Stefan Kaiser, Ursula Kapp, Serge Leyvraz.   

Abstract

Steady-state hematopoiesis and hematopoietic transplantation rely on the unique potential of stem cells to undergo both self-renewal and multilineage differentiation. Fetal liver (FL) represents a promising alternative source of hematopoietic stem cells (HSCs), but limited by the total cell number obtained in a typical harvest. We reported that human FL nonobese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cells (SRCs) could be expanded under simple stroma-free culture conditions. Here, we sought to further characterize FL HSC/SRCs phenotypically and functionally before and following culture. Unexpanded or cultured FL cell suspensions were separated into various subpopulations. These were tested for long-term culture potential and for in vivo repopulating function following transplantation into NOD/SCID mice. We found that upon culture of human FL cells, a tight association between classical stem cell phenotypes, such as CD34(+) /CD38(-) and/or side population, and NOD/SCID repopulating function was lost, as observed with other sources. Although SRC activity before and following culture consistently correlated with the presence of a CD34(+) cell population, we provide evidence that, contrary to umbilical cord blood and adult sources, stem cells present in both CD34(+) and CD34(-) FL populations can sustain long-term hematopoietic cultures. Furthermore, upon additional culture, CD34-depleted cell suspensions, devoid of SRCs, regenerated a population of CD34(+) cells possessing SRC function. Our studies suggest that compared to neonatal and adult sources, the phenotypical characteristics of putative human FL HSCs may be less strictly defined, and reinforce the accumulated evidence that human FL represents a unique, valuable alternative and highly proliferative source of HSCs for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521239     DOI: 10.1089/scd.2006.0096

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  7 in total

1.  The frequency of multipotent CD133(+)CD45RA(-)CD34(+) hematopoietic stem cells is not increased in fetal liver compared with adult stem cell sources.

Authors:  Stefan Radtke; Kevin G Haworth; Hans-Peter Kiem
Journal:  Exp Hematol       Date:  2016-03-22       Impact factor: 3.084

Review 2.  Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms.

Authors:  Halvard Bonig; Thalia Papayannopoulou
Journal:  Methods Mol Biol       Date:  2012

3.  Human fetal liver: an in vitro model of erythropoiesis.

Authors:  Guillaume Pourcher; Christelle Mazurier; Yé Yong King; Marie-Catherine Giarratana; Ladan Kobari; Daniela Boehm; Luc Douay; Hélène Lapillonne
Journal:  Stem Cells Int       Date:  2011-09-22       Impact factor: 5.443

4.  Hepatocellular Carcinoma-propagating Cells are Detectable by Side Population Analysis and Possess an Expression Profile Reflective of a Primitive Origin.

Authors:  Honghai Xia; Jun Cao; Qing Li; Yang Lv; Weidong Jia; Weihua Ren; Qingyu Cheng; Xiaoyuan Song; Geliang Xu
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

5.  Human fetal liver cultures support multiple cell lineages that can engraft immunodeficient mice.

Authors:  Marina E Fomin; Ashley I Beyer; Marcus O Muench
Journal:  Open Biol       Date:  2017-12       Impact factor: 6.411

Review 6.  Innate Lymphoid Cells in the Maternal and Fetal Compartments.

Authors:  Derek Miller; Kenichiro Motomura; Valeria Garcia-Flores; Roberto Romero; Nardhy Gomez-Lopez
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

Review 7.  Innate Lymphoid Cells in Human Pregnancy.

Authors:  João Mendes; Ana Luísa Areia; Paulo Rodrigues-Santos; Manuel Santos-Rosa; Anabela Mota-Pinto
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.